🇺🇸 FDA
Patent

US 11149253

Small molecule compound combination for reprogramming digestive tract derived epithelial cells to endodermal stem/progenitor cells, reprogramming method and application

granted A61KA61K35/12A61P

Quick answer

US patent 11149253 (Small molecule compound combination for reprogramming digestive tract derived epithelial cells to endodermal stem/progenitor cells, reprogramming method and application) held by INSTITUTE OF TRANSFUSION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PEOPLE'S LIBRATION ARMY OF CHINA expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
INSTITUTE OF TRANSFUSION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PEOPLE'S LIBRATION ARMY OF CHINA
Grant date
Tue Oct 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K35/12, A61P, A61P35/00